Post yesterday26 Jun 2025 17:27
1d
Smarter decisions lead to faster drug development. 🧪
With the FDA’s shift away from Maximum Tolerated Dose (MTD) in cancer treatments and the phasing out of mandatory animal testing, the drug development landscape is rapidly evolving. In this dynamic environment, data-driven decisions are essential for navigating complexity, ensuring regulatory compliance, and optimising the path to clinical success.
With over two decades of expertise, our team integrates Model-Informed Drug Development (MIDD), data science, and biostatistics to deliver insights that empower smarter decision-making throughout the drug development process. From preclinical to clinical development, we help our partners streamline drug development, reduce risks, and bring effective treatments to market faster.
As regulatory requirements evolve and the demand for precision medicine grows, MIDD is becoming an indispensable tool for achieving clinical success.